CN111849135A - 一种聚己内酯复合材料及其制备方法 - Google Patents
一种聚己内酯复合材料及其制备方法 Download PDFInfo
- Publication number
- CN111849135A CN111849135A CN202010581497.6A CN202010581497A CN111849135A CN 111849135 A CN111849135 A CN 111849135A CN 202010581497 A CN202010581497 A CN 202010581497A CN 111849135 A CN111849135 A CN 111849135A
- Authority
- CN
- China
- Prior art keywords
- polycaprolactone
- nano
- composite material
- cellulose
- complex enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001610 polycaprolactone Polymers 0.000 title claims abstract description 78
- 239000004632 polycaprolactone Substances 0.000 title claims abstract description 77
- 239000002131 composite material Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229920002678 cellulose Polymers 0.000 claims abstract description 35
- 239000001913 cellulose Substances 0.000 claims abstract description 35
- 102000004190 Enzymes Human genes 0.000 claims abstract description 33
- 108090000790 Enzymes Proteins 0.000 claims abstract description 33
- 239000004367 Lipase Substances 0.000 claims abstract description 25
- 102000004882 Lipase Human genes 0.000 claims abstract description 25
- 108090001060 Lipase Proteins 0.000 claims abstract description 25
- 235000019421 lipase Nutrition 0.000 claims abstract description 25
- 239000002121 nanofiber Substances 0.000 claims abstract description 25
- 238000002156 mixing Methods 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 229920000742 Cotton Polymers 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000003381 stabilizer Substances 0.000 claims abstract description 17
- 239000006087 Silane Coupling Agent Substances 0.000 claims abstract description 16
- 239000000017 hydrogel Substances 0.000 claims abstract description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 9
- 229920001661 Chitosan Polymers 0.000 claims abstract description 9
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims abstract description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 9
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 9
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract description 9
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims abstract description 9
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims abstract description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019253 formic acid Nutrition 0.000 claims abstract description 6
- 238000009489 vacuum treatment Methods 0.000 claims abstract description 5
- 229940124350 antibacterial drug Drugs 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 26
- 238000003756 stirring Methods 0.000 claims description 25
- 239000007864 aqueous solution Substances 0.000 claims description 24
- 238000004108 freeze drying Methods 0.000 claims description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 229920001046 Nanocellulose Polymers 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 abstract description 3
- 230000004048 modification Effects 0.000 abstract description 2
- 238000012986 modification Methods 0.000 abstract description 2
- 238000001291 vacuum drying Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 241000234295 Musa Species 0.000 description 4
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000002861 polymer material Substances 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 238000001132 ultrasonic dispersion Methods 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- QVRCRKLLQYOIKY-UHFFFAOYSA-M 1-methyl-3-prop-2-enylimidazol-1-ium;chloride Chemical compound [Cl-].C[N+]=1C=CN(CC=C)C=1 QVRCRKLLQYOIKY-UHFFFAOYSA-M 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000011208 reinforced composite material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 229920006126 semicrystalline polymer Polymers 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/32—Phosphorus-containing compounds
- C08K2003/321—Phosphates
- C08K2003/325—Calcium, strontium or barium phosphate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K2201/00—Specific properties of additives
- C08K2201/011—Nanostructured additives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2201/00—Properties
- C08L2201/08—Stabilised against heat, light or radiation or oxydation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2205/00—Polymer mixtures characterised by other features
- C08L2205/03—Polymer mixtures characterised by other features containing three or more polymers in a blend
- C08L2205/035—Polymer mixtures characterised by other features containing three or more polymers in a blend containing four or more polymers in a blend
Abstract
本发明涉及一种聚己内酯复合材料及其制备方法。所述聚己内酯复合材料,包括以下步骤:(1)取棉花纳米纤维素、羧甲基纤维素、氯化铁混合加水处理,得纳米纤维素水凝胶;(2)将脂肪酶、稳定剂加到二氯甲烷中混匀,制得复合酶溶液;(3)将纳米纤维素水凝胶加到复合酶溶液中真空处理,干燥后;放到壳聚糖水溶液中处理,干燥,制得复合酶纳米纤维;(4)取聚己内酯、纳米羟基磷灰石粉混合,加到甲酸溶液中处理,制得改性聚己内酯;(5)将改性聚己内酯与复合酶纳米纤维混合,经硅烷偶联剂改性处理,即可。本发明提供的聚己内酯复合材料,具有很好的生物相容性、强度,同时在自然环境中具有良好的速度,可与抗菌药物制成贴剂。
Description
技术领域
本发明属于生物复合材料技术领域,尤其涉及一种聚己内酯复合材料及其制备方法。
背景技术
随着国民受教育程度的提高,人们逐渐意识到保护环境的重要性,所以人们把目光从有毒、难降解的高分子材料转向了无公害、天然有机的高分子材料,并且通过改性得到理想的优质复合材料。但是不可再生资源终究是有限的,为了长久的未来,我们必须利用大自然资源,以解燃眉之急。天然的植物纤维均在大自然中,具有无污染、绿色环保等特点,与天然纤维相比,天然纤维具有不均匀的长度和细度;抗熔性、吸湿性较好;抗静电性好等特点。
聚己内酯是一种热稳定性能较优、与生物的相容性、可降解性优异的半结晶型高分子材。但是,聚己内酯的熔点和分解温度相对较低,降解速度缓慢;所以优先考虑寻找天然、可再生、绿色的自然资源来改性聚己内酯。
纳米纤维素具有质量轻、来源广泛、可降解及比表面积大等优点,它是增强复合材料(如聚己内酯、聚乳酸等)的理想选择。狭义上讲,纳米纤维的直径介于1nm到100nm之间,但从广义上来说,纤维直径低于1000nm的纤维均称为纳米纤维。微米尺度的填料对聚合物力学性能的增强效果甚微,而一些纳米尺度的填料却由于其粒径小,比表面积大以及其表面效应(如小尺寸效应、量子效应和电子隧道效应等)大幅度提高了与聚合物大分子间的作用力,即使纳米粒子在用量很少时,也可以对高分子材料起到明显的增强效果,因此受到广泛的关注。而棉花是其中一种自然资源,它被人类大规模种植。棉花中含有大量棉花纤维素,它是一种可降解和可再生的天然聚合物材料。如果我们对棉花加以利用和开发,这将大大缓解了人类所面临的资源枯竭问题。
目前,纳米纤维素增强聚己内酯材料已被广泛研究。如CN107522789A公开的了一种香蕉纤维素纳米纤维接枝聚己内酯复合材料,将5~10重量份所述香蕉纤维素纳米纤维、10~20重量份1-烯丙基-3-甲基咪唑氯盐,依次放入三口烧瓶中,油浴加热并在80℃下磁力搅拌至香蕉纤维素纳米纤维全部溶解,然后快速升温至130℃后,依次加入10~20重量份ε-己内酯、1~5重量份4-二甲氨基吡啶并混合均匀,在N2保护下反应8h~10h后,加入30~50重量份异丙醇沉淀8h~10h,于4000r/pm下离心10min~15min得沉淀物,将所述沉淀物放入二氯甲烷溶液中浸泡2h~4h,于4000r/pm离心10min~15min后干燥,得香蕉纤维素纳米纤维接枝聚己内酯复合材料。又如文献《纳米孔纤维素凝胶增强聚己内酯的性能研究》(:中国化学会,2013)公开了在具有纳米孔结构的纤维素凝胶内进行己内酯的原位开环聚合,制备出纤维素凝胶/聚己内酯(NCG/PCL)纳米复合材料。
纳米纤维素能有效改善聚己内酯的亲水性,但是其改性后的聚集内酯材料降解速度较缓慢,强度还是较低。
发明内容
为了解决现有技术中存在的上述技术问题,本发明提供了一种聚己内酯复合材料及其制备方法,具体是通过以下技术方案实现的。
一种聚己内酯复合材料的制备方法,包括以下步骤:
(1)取棉花纳米纤维素、羧甲基纤维素、氯化铁混合,加入其质量2倍的水中,在30-40℃搅拌处理30-40min,冷却,离心脱除溶剂,得纳米纤维素水凝胶;
(2)将脂肪酶、稳定剂加到二氯甲烷中搅拌均匀,制得复合酶溶液;
(3)将纳米纤维素水凝胶溶于其3倍的复合酶溶液中,真空处理后,冷冻干燥后,放到壳聚糖水溶液中静置处理30-40min,滤出,在再次冷冻干燥,制发复合酶纳米纤维;
(4)取聚己内酯、纳米羟基磷灰石粉混合,加到其质量5倍得浓度为0.2%的甲酸溶液中,搅拌处理4-5h,超声分散3-5min,冷冻干燥,制得改性聚己内酯;
(5)将改性聚己内酯与复合酶纳米纤维混合,加到硅烷偶联剂水溶液中,水浴搅拌处理后,滤出,冷冻干燥,制得聚己内酯复合材料。
优选地,所述步骤(1),棉花纳米纤维素、羧甲基纤维素、氯化铁的质量比为10:1-2:0.02。
优选地,所述步骤(2),所述脂肪酶为中性脂肪酶;所述稳定剂维生素C有和山梨醇按2:1的质量比混合组成;脂肪酶、稳定剂、二氯甲烷的质量比为1:1-2:10的质量比组成。
优选地,所述步骤(3),真空处理的条件为:真空度-0.07~0.01MPa、时间50-60min;壳聚糖溶液浓度为30-40w%。
优选地,所述步骤(4),纳米羟基磷灰石粉、聚己内酯的质量比为1-3:10。
优选地,所述硅烷偶联剂水溶液为浓度8-10%的KHH50水溶液;改性聚己内酯、复合酶纳米纤维、硅烷偶联剂水溶液的比例为1:0.3-0.5:10的质量比组成。
优选地,水浴搅拌处理的条件为:水浴的温度为40-50℃,搅拌处理2-3h。
本发明的另一目的在于提供一种上述制备方法所制的聚己内酯复合材料。
本发明的另一目的在于提供一种上述聚己内酯材料在生物医药领域的应用,将抗菌药物与聚己内酯复合次材料混合,3D打印贴剂。
本发明的有益效果在于:
1、采用羧甲基纤维素、氯化铁处理纳米纤维素水溶液,能促进纳米纤维素水凝胶的形成,同时能增加纳米纤维素凝胶的强度。
2、采用纳米纤维素凝胶与复合酶溶液混合进行真空处理,在真空处理下,纳米纤维凝胶中的水分渗透出来,复合酶溶液能充分进入到纳米纤维凝胶的网状结构中,干燥后,脂肪酶能固定吸附在纳米纤维中,具有缓慢释放的作用;混合过程中脂肪酶选用中性脂肪酶,并采用稳定剂处理,能抑制纳米纤维素内的活性;混合处理后采用壳聚糖溶液处理,有延长脂肪酶的缓慢释放的作用。
3、采用纳米羟基磷灰石粉改性处理聚己内酯,改性后聚己内酯材料具有良好的耐热性;改性后聚己内酯材料。
4、本发明复合酶纳米纤维与改性聚己内酯材料制成的聚己内酯复合材料,具有很好的生物相容性、强度,同时聚己内酯复合材料在自然环境中具有良好的速度,可作为抗菌贴剂的辅料,与抗菌药物制成贴剂。
具体实施方式
下面结核具体的实施方式来对本发明的技术方案做进一步的限定,但要求保护的范围不仅局限于所作的描述。
实施例1
一种聚己内酯复合材料的制备方法,包括以下步骤:
(1)取棉花纳米纤维素、羧甲基纤维素、氯化铁按10:1:0.02的质量比混合,加入其质量2倍的水中,在30-40℃搅拌处理30min,冷却,离心脱除溶剂,得纳米纤维素水凝胶;
(2)将脂肪酶、稳定剂加到二氯甲烷中搅拌均匀,制得复合酶溶液;
(3)将纳米纤维素水凝胶溶于其3倍的复合酶溶液中,在-0.07~0.01MPa真空度下处理50min后,冷冻干燥后,放到浓度为30%的壳聚糖水溶液中静置处理30min,滤出,在再次冷冻干燥,制发复合酶纳米纤维;
(4)取聚己内酯、纳米羟基磷灰石粉按10:1的质量比混合,加到其质量5倍得浓度为0.2%的甲酸溶液中,搅拌处理4h,超声分散3min,冷冻干燥,制得改性聚己内酯;
(5)将改性聚己内酯与复合酶纳米纤维混合,加到硅烷偶联剂水溶液中,40-50℃水浴搅拌处理2h,滤出,冷冻干燥,制得聚己内酯复合材料。
所述步骤(2),所述脂肪酶为中性脂肪酶;所述稳定剂维生素C有和山梨醇按2:1的质量比混合组成;脂肪酶、稳定剂、二氯甲烷的质量比为1:1-2:10的质量比组成。
所述硅烷偶联剂水溶液为浓度8%的KHH50水溶液;改性聚己内酯、复合酶纳米纤维、硅烷偶联剂水溶液的比例为1:0.3:10的质量比组成。
实施例2
一种聚己内酯复合材料的制备方法,包括以下步骤:
(1)取棉花纳米纤维素、羧甲基纤维素、氯化铁按10:2:0.02的质量比混合,加入其质量2倍的水中,在30-40℃搅拌处理35min,冷却,离心脱除溶剂,得纳米纤维素水凝胶;
(2)将脂肪酶、稳定剂加到二氯甲烷中搅拌均匀,制得复合酶溶液;
(3)将纳米纤维素水凝胶溶于其3倍的复合酶溶液中,在-0.07~0.01MPa真空度下处理55min后,冷冻干燥后,放到浓度为35%的壳聚糖水溶液中静置处理40min,滤出,在再次冷冻干燥,制发复合酶纳米纤维;
(4)取聚己内酯、纳米羟基磷灰石粉按10:3的质量比混合,加到其质量5倍得浓度为0.2%的甲酸溶液中,搅拌处理4.5h,超声分散4min,冷冻干燥,制得改性聚己内酯;
(5)将改性聚己内酯与复合酶纳米纤维混合,加到硅烷偶联剂水溶液中,40-50℃水浴搅拌处理2.5h,滤出,冷冻干燥,制得聚己内酯复合材料。
所述步骤(2),所述脂肪酶为中性脂肪酶;所述稳定剂维生素C有和山梨醇按2:1的质量比混合组成;脂肪酶、稳定剂、二氯甲烷的质量比为1:1:10的质量比组成。
所述硅烷偶联剂水溶液为浓度10%的KHH50水溶液;改性聚己内酯、复合酶纳米纤维、硅烷偶联剂水溶液的比例为1:0.4:10的质量比组成。
实施例3
一种聚己内酯复合材料的制备方法,包括以下步骤:
(1)取棉花纳米纤维素、羧甲基纤维素、氯化铁按10:2:0.02的质量比混合,加入其质量2倍的水中,在30-40℃搅拌处理40min,冷却,离心脱除溶剂,得纳米纤维素水凝胶;
(2)将脂肪酶、稳定剂加到二氯甲烷中搅拌均匀,制得复合酶溶液;
(3)将纳米纤维素水凝胶溶于其3倍的复合酶溶液中,在-0.07~0.01MPa真空度下处理60min后,冷冻干燥后,放到浓度为40%的壳聚糖水溶液中静置处理40min,滤出,在再次冷冻干燥,制发复合酶纳米纤维;
(4)取聚己内酯、纳米羟基磷灰石粉按10:3的质量比混合,加到其质量5倍得浓度为0.2%的甲酸溶液中,搅拌处理4-5h,超声分散5min,冷冻干燥,制得改性聚己内酯;
(5)将改性聚己内酯与复合酶纳米纤维混合,加到硅烷偶联剂水溶液中,40-50℃水浴搅拌处理3h,滤出,冷冻干燥,制得聚己内酯复合材料。
所述步骤(2),所述脂肪酶为中性脂肪酶;所述稳定剂维生素C有和山梨醇按2:1的质量比混合组成;脂肪酶、稳定剂、二氯甲烷的质量比为1:2:10的质量比组成。
所述硅烷偶联剂水溶液为浓度10%的KHH50水溶液;改性聚己内酯、复合酶纳米纤维、硅烷偶联剂水溶液的比例为1:0.5:10的质量比组成。
实施例4
实施例4与实施例1的区别在于是直接采用棉花纳米纤维素而不是复合酶纳米纤维与改性聚己内酯混合制成聚己内酯复合材料;其余过程相同。
实验例1聚己内酯复合材料在土壤中的降解性能研究
取实施例1-4所制成的聚己内酯复合材料样品,以纯聚己内酯为空白对照组,将聚己内酯复合材料与纯聚己内酯在10MPa下压制成1cm的薄片。取一片田园,将制成的薄片放置在深度为20cm的土壤处,每组样品做3个平行样,样品与样品之间距离保持在30cm左右。实验20天,实验期间每隔一段时间取1次样,检测其失重率。结果如表1所示。
表1
5d失重率 | 10d失重率 | 20d失重率 | |
实施例1 | 0.23% | 3.8% | 7.9% |
实施例2 | 0.19% | 4.2% | 8.3% |
实施例3 | 0.21% | 4.1% | 8.1% |
实施例4 | 0.21% | 2.8% | 5.4% |
空白组 | 0.20% | 1.8% | 3.7% |
在此有必要指出的是,以上实施例和试验例仅限于对本发明的技术方案做进一步的阐述和理解,不能理解为对本发明的技术方案做进一步的限定,本领域技术人员作出的非突出实质性特征和显著进步的发明创造,仍然属于本发明的保护范畴。
Claims (9)
1.一种聚己内酯复合材料的制备方法,其特征在于,包括以下步骤:
(1)取棉花纳米纤维素、羧甲基纤维素、氯化铁混合,加入其质量2倍的水中,在30-40℃搅拌处理30-40min,冷却,离心脱除溶剂,得纳米纤维素水凝胶;
(2)将脂肪酶、稳定剂加到二氯甲烷中搅拌均匀,制得复合酶溶液;
(3)将纳米纤维素水凝胶溶于其3倍的复合酶溶液中,真空处理后,冷冻干燥后,放到壳聚糖水溶液中静置处理30-40min,滤出,在再次冷冻干燥,制发复合酶纳米纤维;
(4)取聚己内酯、纳米羟基磷灰石粉混合,加到其质量5倍的浓度为0.2%的甲酸溶液中,搅拌处理4-5h,超声分散3-5min,冷冻干燥,制得改性聚己内酯;
(5)将改性聚己内酯与复合酶纳米纤维混合,加到硅烷偶联剂水溶液中,水浴搅拌处理后,滤出,冷冻干燥,制得聚己内酯复合材料。
2.如权利要求1所述的聚己内酯复合材料的制备方法,其特征在于,所述步骤(1),棉花纳米纤维素、羧甲基纤维素、氯化铁的质量比为10:1-2:0.02。
3.如权利要求1所述的聚己内酯复合材料的制备方法,其特征在于,所述步骤(2),所述脂肪酶为中性脂肪酶;所述稳定剂维生素C有和山梨醇按2:1的质量比混合组成;脂肪酶、稳定剂、二氯甲烷的质量比为1:1-2:10的质量比组成。
4.如权利要求1所述的聚己内酯复合材料的制备方法,其特征在于,所述步骤(3),真空处理的条件为:真空度-0.07~0.01MPa、时间50-60min;壳聚糖溶液浓度为30-40w%。
5.如权利要求1所述的聚己内酯复合材料的制备方法,其特征在于,所述步骤(4),纳米羟基磷灰石粉、聚己内酯的质量比为1-3:10。
6.如权利要求1所述的聚己内酯复合材料的制备方法,其特征在于,所述硅烷偶联剂水溶液为浓度8-10%的KHH50水溶液;改性聚己内酯、复合酶纳米纤维、硅烷偶联剂水溶液的比例为1:0.3-0.5:10的质量比组成。
7.如权利要求1所述的聚己内酯复合材料的制备方法,其特征在于,水浴搅拌处理的条件为:水浴的温度为40-50℃,搅拌处理2-3h。
8.一种如权利要求1-7任一项所述的制备方法所制的聚己内酯复合材料。
9.一种如权利要求1-7任一项所述的制备方法所制的聚己内酯复合材料在生物医药领域的应用,将抗菌药物与聚己内酯复合次材料混合,3D打印贴剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010581497.6A CN111849135A (zh) | 2020-06-23 | 2020-06-23 | 一种聚己内酯复合材料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010581497.6A CN111849135A (zh) | 2020-06-23 | 2020-06-23 | 一种聚己内酯复合材料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111849135A true CN111849135A (zh) | 2020-10-30 |
Family
ID=72988383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010581497.6A Pending CN111849135A (zh) | 2020-06-23 | 2020-06-23 | 一种聚己内酯复合材料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111849135A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116212111A (zh) * | 2023-03-16 | 2023-06-06 | 青岛大学附属医院 | 软骨修复用明胶聚己内酯蛋白肽复合气凝胶及制备方法 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001161360A (ja) * | 1999-12-10 | 2001-06-19 | Nippon Kayaku Co Ltd | 固定化リパーゼ及びそれを用いる有機化合物の製造方法 |
CN101418291A (zh) * | 2008-12-11 | 2009-04-29 | 浙江大学 | 一种溶胶凝胶包埋固定化酶制备s型环戊烯酮的方法 |
US20090162337A1 (en) * | 2007-08-07 | 2009-06-25 | Gross Richard A | Embedded enzymes in polymers to regulate their degradation rate |
CN101514338A (zh) * | 2008-12-04 | 2009-08-26 | 浙江大学 | 采用甲基丙烯酰氧丙基凝胶制备固定化脂肪酶的方法 |
CN102504283A (zh) * | 2011-10-29 | 2012-06-20 | 湖南科技大学 | 一种木质素磺酸盐微小凝胶的制备方法 |
US20130032059A1 (en) * | 2011-08-03 | 2013-02-07 | Trexler Morgana M | Cellulose-Based Hydrogels and Methods of Making Thereof |
CN102965213A (zh) * | 2012-11-29 | 2013-03-13 | 广东工业大学 | 一种在洗衣球外表面包覆壳聚糖缓释膜的方法 |
CN104491867A (zh) * | 2014-11-27 | 2015-04-08 | 广东药学院 | 一种壳聚糖包裹载药蒙脱石的新型给药系统的制备方法 |
CN105566673A (zh) * | 2015-12-17 | 2016-05-11 | 中国科学院兰州化学物理研究所 | 一种多功能纤维素弹性气凝胶的制备方法 |
CN106220896A (zh) * | 2016-07-27 | 2016-12-14 | 盐城工学院 | 一种柔韧和高含水量纤维素/壳聚糖基复合凝胶、其对应的复合膜和应用 |
CN108017888A (zh) * | 2017-12-02 | 2018-05-11 | 无锡福尔顺科技有限公司 | 一种密封聚己内酯包装壳及其应用 |
CN108221079A (zh) * | 2017-12-20 | 2018-06-29 | 东华大学 | 纳米羟基磷灰石聚己内酯纳米晶体复合纤维及其制备方法 |
WO2019058019A1 (en) * | 2017-09-19 | 2019-03-28 | Stick Tech Oy | DENTAL MATERIAL CONTAINING NANOCRYSTALLINE CELLULOSE |
EP3467008A1 (de) * | 2017-10-05 | 2019-04-10 | Deutsches Zentrum für Luft- und Raumfahrt e.V. | Polysaccharid-aerogel-verstärkte kunststoffe |
-
2020
- 2020-06-23 CN CN202010581497.6A patent/CN111849135A/zh active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001161360A (ja) * | 1999-12-10 | 2001-06-19 | Nippon Kayaku Co Ltd | 固定化リパーゼ及びそれを用いる有機化合物の製造方法 |
US20090162337A1 (en) * | 2007-08-07 | 2009-06-25 | Gross Richard A | Embedded enzymes in polymers to regulate their degradation rate |
CN101514338A (zh) * | 2008-12-04 | 2009-08-26 | 浙江大学 | 采用甲基丙烯酰氧丙基凝胶制备固定化脂肪酶的方法 |
CN101418291A (zh) * | 2008-12-11 | 2009-04-29 | 浙江大学 | 一种溶胶凝胶包埋固定化酶制备s型环戊烯酮的方法 |
US20130032059A1 (en) * | 2011-08-03 | 2013-02-07 | Trexler Morgana M | Cellulose-Based Hydrogels and Methods of Making Thereof |
CN102504283A (zh) * | 2011-10-29 | 2012-06-20 | 湖南科技大学 | 一种木质素磺酸盐微小凝胶的制备方法 |
CN102965213A (zh) * | 2012-11-29 | 2013-03-13 | 广东工业大学 | 一种在洗衣球外表面包覆壳聚糖缓释膜的方法 |
CN104491867A (zh) * | 2014-11-27 | 2015-04-08 | 广东药学院 | 一种壳聚糖包裹载药蒙脱石的新型给药系统的制备方法 |
CN105566673A (zh) * | 2015-12-17 | 2016-05-11 | 中国科学院兰州化学物理研究所 | 一种多功能纤维素弹性气凝胶的制备方法 |
CN106220896A (zh) * | 2016-07-27 | 2016-12-14 | 盐城工学院 | 一种柔韧和高含水量纤维素/壳聚糖基复合凝胶、其对应的复合膜和应用 |
WO2019058019A1 (en) * | 2017-09-19 | 2019-03-28 | Stick Tech Oy | DENTAL MATERIAL CONTAINING NANOCRYSTALLINE CELLULOSE |
EP3467008A1 (de) * | 2017-10-05 | 2019-04-10 | Deutsches Zentrum für Luft- und Raumfahrt e.V. | Polysaccharid-aerogel-verstärkte kunststoffe |
CN108017888A (zh) * | 2017-12-02 | 2018-05-11 | 无锡福尔顺科技有限公司 | 一种密封聚己内酯包装壳及其应用 |
CN108221079A (zh) * | 2017-12-20 | 2018-06-29 | 东华大学 | 纳米羟基磷灰石聚己内酯纳米晶体复合纤维及其制备方法 |
Non-Patent Citations (6)
Title |
---|
余晓华等: ""海藻酸钠/壳聚糖包覆尿素微球的制备及其缓释行为"", 《湖北工程学院学报》 * |
李凯: ""新型三维纳米孔纤维素凝胶/聚合物纳米复合材料的构建及其结构与性能"", 《中国优秀博硕士学位论文全文数据库(博士) 工程科技I辑》 * |
李勍等: ""纤维素纳米纤维增强聚合物复合材料研究进展"", 《林业科学》 * |
江连洲: "《酶在大豆制品中的应用》", 31 August 2015, 中国轻工业出版社 * |
王桂英等: "《绿色包装》", 31 August 2016, 东北林业大学出版社 * |
褚红燕等: "《3D打印实训教程》", 30 September 2018, 南京师范大学出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116212111A (zh) * | 2023-03-16 | 2023-06-06 | 青岛大学附属医院 | 软骨修复用明胶聚己内酯蛋白肽复合气凝胶及制备方法 |
CN116212111B (zh) * | 2023-03-16 | 2023-12-22 | 青岛大学附属医院 | 软骨修复用明胶聚己内酯蛋白肽复合气凝胶及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107556495B (zh) | 一种功能性纳米纤维素复合气凝胶的制备方法 | |
Huang et al. | Introduction to nanocellulose | |
Foresti et al. | Applications of bacterial cellulose as precursor of carbon and composites with metal oxide, metal sulfide and metal nanoparticles: A review of recent advances | |
Huang et al. | Nanocellulose: from fundamentals to advanced materials | |
Ma et al. | Synthesis and characterization of injectable self-healing hydrogels based on oxidized alginate-hybrid-hydroxyapatite nanoparticles and carboxymethyl chitosan | |
Lam et al. | Utilizing cellulose from sugarcane bagasse mixed with poly (vinyl alcohol) for tissue engineering scaffold fabrication | |
Mincea et al. | Preparation, modification, and applications of chitin nanowhiskers: a review | |
Wang et al. | Production and characterization of bacterial cellulose membranes with hyaluronic acid and silk sericin | |
CN104975366B (zh) | 一种含纳米颗粒的Lyocell纤维及其制备方法 | |
CN106220867A (zh) | 一种负电性几丁质纳米纤维水凝胶及气凝胶的制备方法 | |
CN111253597B (zh) | 一种甲壳素纳米纤维/聚苯胺复合凝胶膜及其制备方法 | |
CN108084460A (zh) | 一种纤维素/黑磷量子点复合水凝胶及其制备方法 | |
CN103882624A (zh) | 抗水性纳米微晶纤维素/聚乙烯醇/聚丙烯酸/二氧化硅复合纳米纤维膜的制备方法 | |
Cao et al. | Novel spider-web-like nanoporous networks based on jute cellulose nanowhiskers | |
CN110698731A (zh) | 一种多功能复合生物材料、制备方法及其应用 | |
CN105175558A (zh) | 一种复合膜的制备方法 | |
Bi et al. | Construction of chitin functional materials based on a “green” alkali/urea solvent and their applications in biomedicine: Recent advance | |
CN111849135A (zh) | 一种聚己内酯复合材料及其制备方法 | |
CN112076785A (zh) | 一种氮化碳/氢氧化镧纳米纤维膜及其制备方法和用途 | |
Wasim et al. | An overview of Zn/ZnO modified cellulosic nanocomposites and their potential applications | |
CN108396461B (zh) | 一种促愈合纳米纤维膜敷料及其制备方法 | |
CN113292762B (zh) | 一种双醛纳米纤维素三维柔性材料及其制备方法与应用 | |
KR20210117234A (ko) | 나노바이오복합필름 및 이의 제조 방법 | |
Latif et al. | Carbon quantum dots (CQDs) modified polymers: a mini review of non-optical applications | |
CN110983756B (zh) | 一种棉织物面料的防紫外整理方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201030 |
|
RJ01 | Rejection of invention patent application after publication |